ASH Clinical Practice Guidelines on Diagnosis and Treatment of Amyloidosis
ASH Seeks Public Comment on Draft Recommendations Guidelines on Treatment of AL Amyloidosis
ASH is now accepting public comments on draft recommendations for Treatment of AL Amyloidosis. Comments will be accepted until July 7, 2026. We encourage all interested healthcare professionals, stakeholder organizations, and individuals to share their feedback on these draft recommendations. All comments will be reviewed by the guideline panel before the guidelines are finalized.
Please submit all comments to [email protected].
Over recent years, growing knowledge and advances in diagnostic approaches have enhanced the recognition of light chain (AL) amyloidosis. The purpose of these guidelines is to provide evidence-based recommendations to facilitate early and accurate diagnosis of AL amyloidosis. A second panel covering the treatment of AL amyloidosis will follow.
Amyloidosis is a rare group of disorders caused by protein misfolding. In North America, one of the common forms of amyloidosis is light chain amyloidosis (AL). These guidelines are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis and treatment of AL.
Guideline Implementation Tools and Resources
Visual Summary
This concise visual aid is intended to support understanding of the recommendations and to aid in clinical decision-making:
Teaching Slides
These educational slides are intended to teach about diagnosis of amyloidosis.
Pocket Guide
This brief, evidence-based pocket guide is intended to help physicians provide quality care to patients.
Quality Metrics Assessment Tool
This set of metrics is intended to assess compliance with the ASH Clinical Practice Guidelines on Diagnosis of Light Chain Amyloidosis. Use this tool to identify quality gaps at your institution and improve care for patients with light chain amyloidosis.